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Results: Cartilage pentosidine (a marker of AGE) levels were ~5 fold
enhanced (p =0.001 vs. PBS injected joints). The macroscopic and
microscopic damage was similar for the AGEd and PBS injected joints
(macroscopic score of 1 of a max score of 4 and histological OARSI score
of 3–5 of a max score of 36, respectively). For the PG synthesis (5.09±0.29
vs 4.64±0.32) % total and newly formed PG (23.29±1.88 vs 23.66±2.02
and 43.02±2.23 vs 43.75±2.4), as well as the PG content (31.20±1.17
vs 30.83±0.98) no statistically difference could be found between both
groups. This was not expected and therefore no control (untouched)
and OA (experimentally induced according to the classic Groove model)
joint were included in the study. Therefore, the biochemical data were
compared to historical controls of the most recent study using the Groove
model. Comparing these results, it demonstrates that the AGEd joints
are in general in between the PBS injected joints and the experimental
early OA joints (for example PG content 31.20±1.17 vs 30.83±0.98 vs
30.44±1.52). The PBS injected joints are in between the normal healthy
joints and the AGEd joints. Assuming a stepwise increase in severity of
damage there was a clear correlation between severity of damage and the
different conditions from healthy control joints, via PBS injected joints
with minimally surgically damage, AGEd joints with minimal surgical
damage, to experimentally induced OA joints according to the Groove
model (PG synthesis r = −0.873, % total and newly formed PG release
r = 0.971, p = 0.029 and r = 0.954, p = 0.046, and PG content r = 0.836).
Conclusions: Despite the fact that enhanced cross-linking of
macromolecules by the AGEs restrains loss of proteoglycans,
corroborating the diminished turnover of old cartilage, and a tendency
toward enhanced cartilage damage in the artiﬁcially aged joints, the
present data do not clearly support a role for enhanced cartilage AGE
levels in development of joint degeneration.
Biomarkers
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A UNIQUE DEAMIDATED CARTILAGE OLIGOMERIC MATRIX
PROTEIN (COMP) BIOMARKER PREFERENTIALLY IDENTIFIES HIP
OSTEOARTHRITIS
J. Catterall1, M-F. Hsueh1, T.V. Stabler1, J.M. Renner2, J.M. Jordan2,
V.B. Kraus1. 1Duke Univ., Durham, NC, USA; 2UNC, Chapel Hill, NC, USA
Purpose. As extracellular proteins age, they undergo and accumulate
non-enzymatic post-translational modiﬁcations that cannot be repaired.
As a tissue, such as cartilage, with a relatively slow protein turnover
ages, the levels of these modiﬁed proteins will increase. This allows the
exciting possibility of being able to distinguish “older” matrix proteins
released by catabolism, from turnover of newly synthesized proteins
or proteins released during times of frustrated repair. We hypothesized
that these modiﬁed proteins could be used to systemically monitor
loss of extracellular matrix due to chronic arthritic diseases such as
osteoarthritis (OA).
Method. To test this hypothesis, we predicted sites of deamidation in
human cartilage oligomeric matrix protein (COMP) and conﬁrmed, by
mass spectroscopy, the presence of deamidated (Asp64) and native
(Asn64) COMP epitopes [mean 0.95% deamidated COMP (D-COMP)
relative to native COMP] in cartilage. We developed monoclonal
antibodies speciﬁc to the deamidated Asp64 COMP region and a D-COMP
speciﬁc ELISA using the 6–1A12 monoclonal antibody, one of our newly
developed D-COMP speciﬁc antibodies. This new ELISA was used to
measure D-COMP in extracts from human cartilage and in human serum
to determine the utility of D-COMP as a novel biomarker for OA. For
comparison we determined the levels of serum Total COMP by ELISA
(antibodies 16-F12 and 17-C10). Cartilage extracts were prepared from
Duke IRB approved surgical waste cartilage, by grinding under liquid
nitrogen, two 4M Guanidine-HCL extractions before dialysis into PBS.
Results. In the Duke BAJA joint replacement study (n =14, mean age
63.4±13.2 yrs; 64% men; 4 hip and 10 knee replacements), serum
D-COMP (p =0.017), but not Total COMP (p =0.5), declined signiﬁcantly
after replacement suggesting an association of serum D-COMP levels with
OA joints. In 450 participants from the Johnston County Osteoarthritis
Project, D-COMP was associated with hip (p < 0.0001) but not knee
(p =0.95) OA severity as deﬁned by increasing Kellgren-Lawrence (KL)
grade. In contrast, Total COMP was associated with knee (p < 0.0001) but
not hip (p =0.47) KL grade. To further investigate D-COMPs association
with hip OA, we determined Total and D-COMP levels in hip (n =11; mean
age 77.3±11.3; 57–90 yrs) and knee cartilage extracts (n = 15; mean age
66.5±8.9; 54–88 yrs). D-COMP was higher in cartilage soluble proteins
extracted from hip proximal to OA lesions compared to macroscopically
normal hip (p = 0.007), or macroscopically normal and OA knee (p < 0.01)
cartilage. Total COMP did not vary by joint site or proximity to the
lesion.
Conclusions. Enrichment of deamidated epitope in hip cartilage likely
indicates a lesser repair response of hip compared with knee cartilage.
This study demonstrates the presence of D-COMP in articular cartilage
and the systemic circulation and to our knowledge, is the ﬁrst biomarker
to show speciﬁcity for a particular joint site.
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Purpose: Several OA biomarkers are currently in development at
different validation stages. Unfortunately, there is no proven method
or test available to identify individuals at risk of developing primary OA,
or to identify which of the affected individuals may require treatment
due to the risk of disease progression. In this context, we have previously
identiﬁed Pitx1, a homeobox transcription factor, as a relevant OA
candidate gene. Indeed, a loss of PITX1 expression was determined
in patients suffering from primary knee joint OA. Recently, we have
identiﬁed Prohibitin (PHB1) as part of the transcriptional repressor
complex turning-off PITX1 expression in OA. Taking into account the
postulated role for PHB1 in cellular senescence and mitochondria
functions, it is conceivable that aberrant nuclear accumulation of PHB1
in primary OA could be detected not only in articular chondrocytes but
also in other cell types especially if this event is caused by genetic
predispositions.
Methods: To verify this assumption, cytosolic and nuclear fractions of
lymphocytes obtained from 88 consecutive OA patients and 33 aged-
matched control subjects were performed by Western blot while nuclear
localization of PHB1 in lymphocytes of OA patients (surgical cases)
was also detected using immunoﬂuorescence methods and confocal
microscopy. Plasma PHB1 levels were determined by an ELISA assay.
Results: Increased nuclear localization of PHB1 in lymphocytes of
OA patients (surgical cases) was detected by Western blot and
immunoﬂuorescence methods when compared to age-matched healthy
controls. Moreover, elevation in the number of nuclear aggregates
positive for PHB1 correlated with disease severity (KL score).
Interestingly, mean plasma PHB1 levels were signiﬁcantly decreased
in OA patients with an average value of 15.8 ng/ml and 21.4 ng/ml for
knee OA and hip OA groups when compared to the healthy control group
(30.1 ng/ml). This reduction in circulating PHB1 levels could be explained
by its nuclear retention.
Conclusions: Here we report a molecular mechanism that can help
to better stratify OA patients and the usefulness of PHB1 as OA
blood biomarker. Furthermore, our clinical data have the merit of
unifying previous concepts and ﬁndings proposed to better deﬁne OA
pathogenesis, such as mitochondrial dysfunction or cellular aging.
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EARLY DECREASE OF SERUM BIOMARKERS OF TYPE II COLLAGEN
DEGRADATION (Coll2–1) AND JOINT INFLAMMATION (Coll2–1NO2)
BY HYALURONIC ACID INTRA-ARTICULAR INJECTIONS IN PATIENTS
WITH KNEE OSTEOARTHRITIS
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Purpose: Viscosupplementation (VS) by intra articular (IA) injection
of hyaluronic acid (HA) is used to reduce pain in patients with knee
